Jasper Therapeutics
JSPR
46 hedge funds and large institutions have $120M invested in Jasper Therapeutics in 2023 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 11 closing their positions.
235% more call options, than puts
Call options by funds: $114K | Put options by funds: $34K
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
5% more funds holding
Funds holding: 44 → 46 (+2)
0.57% less ownership
Funds ownership: 8.56% → 7.98% (-0.57%)
29% less capital invested
Capital invested by funds: $169M → $120M (-$48.8M)
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$4.26M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.17M |
| 3 |
Mariner
Overland Park,
Kansas
|
+$1.06M |
| 4 |
JFG
Jefferies Financial Group
New York
|
+$728K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$699K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$7.24M |
| 2 |
RI
RTW Investments
New York
|
-$4.22M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.84M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$2.84M |
| 5 |
Jane Street
New York
|
-$382K |
JSPR Hedge Fund Activity: Q2 2023 in Review
46 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q2 2023, worth a combined $120M — down 29% from $169M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new JSPR positions and 11 closed out — a net gain of 2 holders — while 7 added to existing stakes and 10 trimmed.
The largest buyer was Altium Capital Management, opening a new position worth an estimated $4.26M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $7.24M sold.
- 46 institutional investors held Jasper Therapeutics (JSPR) as of Q2 2023, up from 44 in Q1 2023.
- Funds reported $120M of Jasper Therapeutics stock for Q2 2023, down 29% quarter-over-quarter.
- 13 funds opened new Jasper Therapeutics positions in Q2 2023 and 11 closed out, a net change of +2 holders.
- The largest Jasper Therapeutics buyer in Q2 2023 was Altium Capital Management, an estimated $4.26M added.
- The largest Jasper Therapeutics seller in Q2 2023 was Driehaus Capital Management, an estimated $7.24M sold.
Based on aggregated 13F filings for Q2 2023.